Brazil clears first Ozempic generic

The global landscape for diabetes and weight-loss treatments is shifting as regulatory barriers fall for generic alternatives to Novo Nordisk’s flagship medication, semaglutide. Following similar developments in India and Canada, Brazil has officially cleared the path for the production and distribution of legal copies of the drug.

Did You Know? Brazilian authorities have already demonstrated a rigorous screening process for these medications, having previously rejected four applications from Indian manufacturers due to insufficient evidence regarding the safety, quality and efficacy of their proposed products.

The Arrival of Ozivy

The Brazilian pharmaceutical firm EMS has received regulatory approval to market its version of the drug under the brand name Ozivy. Designed for adults living with type 2 diabetes, the product is expected to reach the market within 30 days.

Consumers may see a significant shift in affordability, as the company plans to price the generic version approximately 30% lower than the original product. EMS intends to roll out the medication in 0.25 mg, 0.5 mg, and 1 mg doses, with the latter expected to capture a substantial portion of the local market.

Expert Insight: The expiration of patents on semaglutide in several major markets this year marks a critical turning point. As competition intensifies, the primary challenge for regulators will be balancing the urgent public demand for more accessible treatments with the necessity of maintaining stringent safety and efficacy standards for generic pharmaceutical entries.

Market Implications and Future Outlook

The entry of EMS into the space is a major financial development, with CEO Marcus Sanchez projecting sales of 1.2 million doses in the first year alone. This volume is anticipated to generate roughly USD 100 million for the company.

As for the broader market, the landscape is likely to become more crowded. Brazilian authorities are currently reviewing six additional applications for semaglutide copies. If these applications meet the necessary quality and safety benchmarks, patients could soon have a wider array of options, potentially driving further market competition.

Frequently Asked Questions

What is Ozivy?

Ozivy is a generic version of the diabetes medication semaglutide, produced by the Brazilian pharmaceutical company EMS for the treatment of adults with type 2 diabetes.

Custo com inovação nas farmacêuticas vai explodir, diz Marcus Sanchez, da EMS

How much cheaper will the generic version be?

The company expects to launch Ozivy at a price point approximately 30% lower than the original Novo Nordisk product.

Are other versions of this drug expected to enter the Brazilian market?

Yes, Brazilian authorities are currently in the process of reviewing six other applications for semaglutide copies, following previous rejections of four applications from Indian manufacturers.

How do you think the increased availability of generic versions will impact the long-term accessibility of diabetes care in your region?